Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 5/20 | 0.49 |
| ▸ | MET | P08581 | 11/20 | 0.47 |
| ▸ | KDR | P35968 | 2/20 | 0.47 |
| ▸ | SRC | P12931 | 3/20 | 0.46 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4774400 | 0.93 | AXL (0.51) | AXLMETKDRSRCTGFBR1 | |
| SCHEMBL5186596 | 0.80 | MET (0.53) | AXLMETKDRSRCTGFBR1 | |
| SCHEMBL1396676 | 0.75 | KDR (0.46) | AXLMETKDRSRCPDGFRA | |
| SCHEMBL5305342 | 0.75 | MET (0.48) | AXLMETKDRSRCTGFBR1 | |
| SCHEMBL5304436 | 0.74 | MET (0.52) | AXLMETKDRSRCTGFBR1 | |
| SCHEMBL1396733 | 0.73 | MET (0.51) | AXLMETKDRSRCTGFBR1 | |
| SCHEMBL2325654 | 0.72 | MET (0.52) | METKDRSRCTGFBR1PDGFRA | |
| SCHEMBL5307620 | 0.71 | MET (0.53) | AXLMETKDRFLT3 | |
| SCHEMBL15338419 | 0.70 | SRC (0.70) | AXLMETKDRSRCTGFBR1 | |
| SCHEMBL5054285 | 0.70 | MET (0.57) | AXLMETKDRSRCTGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2288383-A1 | COMBINATIONS VEGF(R) INHIBITORS AND HEPATOCYTE GROWTH FACTOR (C-MET) INHIBITORS FOR THE TREATMENT OF CANCER | Amgen, Inc (US) | 2011-03-02 | — | — | EP | claimed |
| WO-2009140549-A1 | COMBINATIONS VEGF(R) INHIBITORS AND HEPATOCYTE GROWTH FACTOR (C-MET) INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2009-11-19 | — | — | WO | claimed |
| EP-1881976-A1 | SUBSTITUTED AMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Amgen Inc., (US) | 2008-01-30 | — | — | EP | claimed |
| WO-2006116713-A1 | SUBSTITUTED AMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS | AMGEN INC. (US) | 2006-11-02 | — | — | WO | claimed |
| EP-2288383-A1 | COMBINATIONS VEGF(R) INHIBITORS AND HEPATOCYTE GROWTH FACTOR (C-MET) INHIBITORS FOR THE TREATMENT OF CANCER | Amgen, Inc (US) | 2011-03-02 | — | — | EP | disclosed |
| EP-1881976-A1 | SUBSTITUTED AMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Amgen Inc., (US) | 2008-01-30 | — | — | EP | disclosed |
| WO-2006116713-A1 | SUBSTITUTED AMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS | AMGEN INC. (US) | 2006-11-02 | — | — | WO | disclosed |